The translatability of animal models for clinical development: Biomarkers and disease models

Current Opinion in Pharmacology

Volumn 10, Issue 5, 2010, Pages 601-606

  Wendler, Alexandra ^a   Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; PROBUCOL SUCCINATE; TORCETRAPIB;

ATHEROSCLEROSIS; BIOMEDICINE; CANCER RESEARCH; CARDIOVASCULAR DISEASE; DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ENDOMETRIOSIS; GENERAL ASPECTS OF DISEASE; GENETIC ENGINEERING; GENOMICS; HEART FAILURE; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TUMOR XENOGRAFT;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; TRANSLATIONAL RESEARCH;

EID: 77956651943     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.05.009     Document Type: Review

References (34)

1. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003, 2:566-580.
2. Wehling M Defining biomarkers as the most important contributors to translational science. Principles of Translational Science in Medicine 2009, 175-180. Cambridge University Press. M. Wehling (Ed.).
3. Wehling M. Translational medicine: can it really facilitate the transition of research " from bench to bedside" ?. Eur J Clin Pharmacol 2006, 62:91-95.
4. Wehling M Predictivity classification of biomarkers and scores. Principles of Translational Science in Medicine 2009, 197-206. Cambridge University Press. M. Wehling (Ed.).
5. Russell J.C., Proctor S.D. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 2006, 15:318-330.
6. Johannson L Translational imaging research. Principles in Translational Science in Medicine 2009, 240-250. Cambridge University Press. M. Wehling (Ed.).
7. Flecknell P. Replacement, reduction and refinement. ALTEX 2002, 19:73-78.
8. Kim R.J., Fieno D.S., Parrish T.B., Harris K., Chen E.L., Simonetti O., Bundy J., Finn J.P., Klocke F.J., Judd R.M. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999, 100:1992-2002.
9. Pinto Y.M., Paul M., Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998, 39:77-88.
10. Lind L Typical examples of translational biomarkers. Principles in Translational Science in Medicine 2009, 220-235. Cambridge University Press. M. Wehling (Ed.).
11. Yanni A.E. The laboratory rabbit: an animal model of atherosclerosis research. Lab Anim 2004, 38:246-256.
12. Fan J., Watanabe T. Cholesterol-fed and transgenic rabbit models for the study of atherosclerosis. J Atheroscler Thromb 2000, 7:26-32.
13. Zadelaar S., Kleemann R., Verschuren L., de Vries-Van der Weij J., van der Hoorn J., Princen H.M., Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721.
14. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 1998, 39:60-76.
15. Geyer H.J., Scheuntert I., Rapp K., Kettrup A., Korte F., Greim H., Rozman K. Correlation between acute toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and total body fat content in mammals. Toxicology 1990, 65:97-107.
16. Ernst S., Boyer S., Platz S. Pharmaceutical toxicology. Principles of Translational Science in Medicine 2009, 299-326. Cambridge University Press. M. Wehling (Ed.).
17. Stevens J.L. Future of toxicology-mechanisms of toxicity and drug safety: where do we go from here?. Chem Res Toxicol 2006, 19:1393-1401.
18. Vaidya V.S., Ramirez V., Ichimura T., Bobadilla N.A., Bonventre J.V. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006, 290:F517-529.
19. Matsunari H., Nagashima H. Application of genetically modified and cloned pigs in translational research. J Reprod Dev 2009, 55:225-230.
20. Rogers C.S., Hao Y., Rokhlina T., Samuel M., Stoltz D.A., Li Y., Petroff E., Vermeer D.W., Kabel A.C., Yan Z., et al. Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. J Clin Invest 2008, 118:1571-1577.
21. Rogers C.S., Abraham W.M., Brogden K.A., Engelhardt J.F., Fisher J.T., McCray P.B., McLennan G., Meyerholz D.K., Namati E., Ostedgaard L.S., et al. The porcine lung as a potential model for cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2008, 295:L240-263.
22. Petters R.M., Alexander C.A., Wells K.D., Collins E.B., Sommer J.R., Blanton M.R., Rojas G., Hao Y., Flowers W.L., Banin E., et al. Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa. Nat Biotechnol 1997, 15:965-970.
23. Yang S.H., Cheng P.H., Banta H., Piotrowska-Nitsche K., Yang J.J., Cheng E.C., Snyder B., Larkin K., Liu J., Orkin J., et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008, 453:921-924.
24. Wang C.E., Tydlacka S., Orr A.L., Yang S.H., Graham R.K., Hayden M.R., Li S., Chan A.W., Li X.J. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet 2008, 17:2738-2751.
25. Chan A.W., Yang S.H. Generation of transgenic monkeys with human inherited genetic disease. Methods 2009, 49:78-84.
26. D'Hooghe T.M., Kyama C.M., Chai D., Fassbender A., Vodolazkaia A., Bokor A., Mwenda J.M. Nonhuman primate models for translational research in endometriosis. Reprod Sci 2009, 16:152-161.
27. Sharkey F.E., Fogh J. Considerations in the use of nude mice for cancer research. Cancer Metastasis Rev 1984, 3:341-360.
28. Schuler W., Weiler I.J., Schuler A., Phillips R.A., Rosenberg N., Mak T.W., Kearney J.F., Perry R.P., Bosma M.J. Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. Cell 1986, 46:963-972.
29. Mather S. Molecular imaging with bioconjugates in mouse models of cancer. Bioconjug Chem 2009, 20:631-643.
30. Greiner D.L., Hesselton R.A., Shultz L.D. SCID mouse models of human stem cell engraftment. Stem Cells 1998, 16:166-177.
31. Christianson S.W., Greiner D.L., Schweitzer I.B., Gott B., Beamer G.L., Schweitzer P.A., Hesselton R.M., Shultz L.D. Role of natural killer cells on engraftment of human lymphoid cells and on metastasis of human T-lymphoblastoid leukemia cells in C57BL/6J-scid mice and in C57BL/6J-scid bg mice. Cell Immunol 1996, 171:186-199.
32. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., Ueyama Y., Koyanagi Y., Sugamura K., Tsuji K., et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
33. de Jong M, Maina T: Of mice and humans: are they the same?-implications in cancer translational research. J Nucl Med 2010, 51:501-504.
34. Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success?. Nat Rev Drug Discov 2009, 8:541-546.